Cancer Family
Malignant Mesothelioma
CI-CAN-00000240Explore in graph →
Top-level96 active trials4 approved drugs11 evidence items
- NCIt
- C4456
- ICD-10
- C45
- DOID
- 1790
- MeSH
- D000086002
- MeSH
- D008654
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000240Explore in graph →
Clinical trials
478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (81)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00541073 | Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery(ALIMESO) | completed | Phase 2 | 60 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03654833 | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma(MiST) | completed | Phase 2 | 186 | University of LeicesterOTHER | 1 | Aug 17, 2026 |
| clinicaltrials |
| NCT05278975 | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | completed | Phase 1 / Phase 2 | 50 | RS Oncology LLCINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02399371 | Pembrolizumab in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 65 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT00797719 | Short Neoadjuvant Hemithoracic IMRT for MPM | completed | Phase 1 / Phase 2 | 104 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02662504 | Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma(MesoPDT) | completed | Phase 2 | 6 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05136677 | A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants(CheckMate 6DW) | completed | Phase 2 | 102 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05380713 | ......SMARTEST Trial...... | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05005429 | Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma(BIMES) | completed | Phase 2 | 47 | Fundación GECPOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT02611037 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT05449366 | Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma(INTERACT MESO) | completed | Phase 1 / Phase 2 | 7 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00354393 | Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 9 | The Cleveland ClinicOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT02078700 | Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. | completed | Phase 2 | 40 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05455424 | Niraparib Efficacy in Patient With Unresectable Mesothelioma(NERO) | completed | Phase 2 | 88 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02649829 | Autologous Dendritic Cell Vaccination in Mesothelioma(MESODEC) | completed | Phase 1 / Phase 2 | 28 | University Hospital, AntwerpOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03560973 | A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM(RAMES) | completed | Phase 2 | 164 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04177953 | Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery | completed | Phase 2 | 92 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT02784171 | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 / Phase 3 | 520 | Canadian Cancer Trials GroupNETWORK | 3 | Dec 10, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01265433 | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | completed | Phase 2 | 41 | Sellas Life Sciences GroupINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05660616 | Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 40 | Ain Shams UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT03610360 | DENdritic Cell Immunotherapy for Mesothelioma(DENIM) | completed | Phase 2 / Phase 3 | 176 | Amphera BVINDUSTRY | 5 | Feb 1, 2024 | clinicaltrials |
| NCT05041062 | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT03399552 | Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | completed | Phase 1 / Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02709512 | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(ATOMIC) | completed | Phase 2 / Phase 3 | 249 | Polaris GroupINDUSTRY | 5 | Oct 4, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT01486368 | A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02899195 | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma(PrE0505) | completed | Phase 2 | 55 | PrECOG, LLC.OTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00101283 | Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 | 32 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04115111 | Diadem to Investigate the Activity and Safety of Durvalumab(Diadem) | completed | Phase 2 | 57 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT00651456 | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study(MAPS) | completed | Phase 2 / Phase 3 | 448 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT02293005 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02592551 | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | completed | Phase 2 | 24 | Baylor College of MedicineOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma(Amatuximab) | completed | Phase 2 | 89 | MorphotekINDUSTRY | 5 | Sep 22, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02568449 | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT02139904 | Vinorelbine in Mesothelioma(VIM) | completed | Phase 2 | 154 | Wales Cancer Trials UnitOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT01085630 | Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy | completed | Phase 2 | 72 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03213301 | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | completed | Phase 2 | 42 | Swiss Cancer InstituteOTHER | 2 | Jul 14, 2021 | clinicaltrials |
| NCT02860286 | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | completed | Phase 2 | 74 | Epizyme, Inc.INDUSTRY | 3 | Apr 9, 2021 | clinicaltrials |
| NCT03531840 | Olaparib in People With Malignant Mesothelioma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2021 | clinicaltrials |
| NCT02716272 | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients(MAPS2) | completed | Phase 2 | 125 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02049060 | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin | completed | Phase 1 / Phase 2 | 31 | Armando Santoro, MDOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02303899 | Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma | completed | Phase 2 | 22 | Istituto Clinico HumanitasOTHER | 1 | Jan 22, 2021 | clinicaltrials |
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials